Quipt Home Medical Corp - Ordinary Shares New Forecast, price target & analysts
Quipt Home Medical Corp - Ordinary Shares New Target price 2025 - Analyst rating & recommendation
Quipt Home Medical Corp - Ordinary Shares New Classifications & Recommendation:
Quipt Home Medical Corp - Ordinary Shares New Price Target
| Target Price | $4.08 |
| Price | $2.57 |
| Potential |
58.67%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Quipt Home Medical Corp - Ordinary Shares New 2026 .
The average Quipt Home Medical Corp - Ordinary Shares New target price is $4.08.
This is
58.67%
register free of charge
$5.05
96.33%
register free of charge
$1.67
35.17%
register free of charge
|
|
| A rating was issued by 11 analysts: 9 Analysts recommend Quipt Home Medical Corp - Ordinary Shares New to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Quipt Home Medical Corp - Ordinary Shares New stock has an average upside potential 2026 of
58.67%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
| Sep '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 245.92 | 244.50 |
| 10.92% | 0.58% | |
| EBITDA Margin | 18.70% | 23.08% |
| 8.48% | 23.41% | |
| Net Margin | -2.75% | -3.50% |
| 117.65% | 27.33% |
6 Analysts have issued a sales forecast Quipt Home Medical Corp - Ordinary Shares New 2025 . The average Quipt Home Medical Corp - Ordinary Shares New sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Quipt Home Medical Corp - Ordinary Shares New EBITDA forecast 2025. The average Quipt Home Medical Corp - Ordinary Shares New EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Quipt Home Medical Corp - Ordinary Shares New Analysts have issued a net profit forecast 2025. The average Quipt Home Medical Corp - Ordinary Shares New net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
| Sep '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.16 | -0.20 |
| 128.57% | 25.00% | |
| P/E | negative | |
| EV/Sales | 0.79 |
6 Analysts have issued a Quipt Home Medical Corp - Ordinary Shares New forecast for earnings per share. The average Quipt Home Medical Corp - Ordinary Shares New EPS is
This results in the following potential growth metrics and future valuations:
Quipt Home Medical Corp - Ordinary Shares New...
Current Quipt Home Medical Corp - Ordinary Shares New Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| THE BENCHMARK COMPANY LLC |
Locked
➜
Locked
|
Locked | Aug 29 2025 |
| CANACCORD GENUITY |
Locked
➜
Locked
|
Locked | Aug 28 2025 |
| STIFEL CANADA |
Locked
➜
Locked
|
Locked | Aug 12 2025 |
| LEEDE JONES GABLE |
Locked
➜
Locked
|
Locked | Aug 12 2025 |
| STIFEL CANADA |
Locked
➜
Locked
|
Locked | May 21 2025 |
| STIFEL CANADA |
Locked
➜
Locked
|
Locked | May 20 2025 |
| THE BENCHMARK COMPANY LLC |
Locked
➜
Locked
|
Locked | May 14 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
THE BENCHMARK COMPANY LLC:
Locked
➜
Locked
|
Aug 29 2025 |
|
Locked
CANACCORD GENUITY:
Locked
➜
Locked
|
Aug 28 2025 |
|
Locked
STIFEL CANADA:
Locked
➜
Locked
|
Aug 12 2025 |
|
Locked
LEEDE JONES GABLE:
Locked
➜
Locked
|
Aug 12 2025 |
|
Locked
STIFEL CANADA:
Locked
➜
Locked
|
May 21 2025 |
|
Locked
STIFEL CANADA:
Locked
➜
Locked
|
May 20 2025 |
|
Locked
THE BENCHMARK COMPANY LLC:
Locked
➜
Locked
|
May 14 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
